Neuroleptic malignant syndrome, a dangerous complication of neuroleptic treatment, was first reported in the French literature in the 1960’s. Although long assumed to be rare, the syndrome has beat widely reported recently, particularly in the United States. Does this surge of reports reflect a true increase in the frequency of the syndrome, or merely increased scientific interest in the disorder? A review of available epidemiologic data favors the latter possibility: the syndrome probably continues to affect about 1% of neuroleptic-treated patients, a figure little different from the original French estimate more titan 20 years ago.